Geographic and Racial Disparities in Access to Chimeric Bispecific Antibodies Trials for Multiple Myeloma

JAMA Network Open

5, e2228877

DOI: 10.1001/jamanetworkopen.2022.28877

Citation Report

#	Article	IF	Citations
1	Chimeric Antigen Receptor T-Cell Therapy for Patients With Multiple Myelomaâ€"A Call for Equal Opportunity. JAMA Oncology, 2023, 9, 297.	3.4	1
2	Multisite Quality Improvement Initiative to Identify and Address Racial Disparities and Deficiencies in Delivering Equitable, Patient-Centered Care for Multiple Myelomaâ€"Exploring the Differences between Academic and Community Oncology Centers. Current Oncology, 2023, 30, 1598-1613.	0.9	2
3	Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2023, 29, 440-448.	0.6	9
11	Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States. Bone Marrow Transplantation, 0, , .	1.3	0
17	Expanding access to CAR T cell therapies through local manufacturing. Nature Biotechnology, 2023, 41, 1698-1708.	9.4	3
18	Addressing the disparities: the approach to the African American patient with multiple myeloma. Blood Cancer Journal, 2023, 13, .	2.8	1